GSK Reports the CHMP’s Positive Opinion of Menveo Vaccine Against Invasive Meningococcal Disease
Shots:
- The CHMP has granted positive opinion to a single-vial, fully liquid formulation of Menveo (MenACWY vaccine) against invasive meningococcal disease. It is intended for active immunization in children (from 2yrs.), adolescents & adults
- The opinion was based on two P-IIb studies assessing Meningococcal ACWY conjugate vaccines (GSK3536820A & Menveo) in healthy adults (18-40yrs.) and in adolescents & young adults (10-40yrs.), respectively
- The studies 1 & 2EPs demonstrated the vaccine’s similar immunogenicity, tolerability & safety to the current lyophilized/liquid version. The EC's final decision is anticipated in Nov 2024
Ref: GSK | Image: GSK
Related News:- GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
